



27 APR 2022

FDA ADVISORY
No. 2022-0996

TO: ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC

SUBJECT: Public Health Warning Against the Purchase and Use of the following Misbranded Face Masks in Foreign Character:

1. NANJIREN FACE MASK 20 PCS
2. KF94 MASK BLACK

The Food and Drug Administration (FDA) warns all healthcare professionals and the general public **NOT TO PURCHASE AND USE** the following misbranded face masks in foreign characters:



Figure 1. Misbranded Face Mask in Foreign Characters – Nanjiren Face Masks 20 pcs





Figure 2. Misbranded Face Mask in Foreign Characters – KF94 Mask Black

The FDA verified through post-marketing surveillance that the abovementioned medical device products are being offered for sale in the local market.

Section 19(c) of Republic Act (RA) No. 3720 also known as the “Food, Drug, and Cosmetic Act” as amended by RA No. 9711 otherwise known as the “Food and Drug Administration (FDA) Act of 2009” states that “a device shall be deemed misbranded if any word, statement, or other information required by or under authority of this Act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use”. The above-mentioned products are considered misbranded and the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, non-consumer use, promotion, advertising, or sponsorship of any health product that is misbranded is prohibited pursuant to Section 10 of RA No. 9711.

All concerned establishments are warned not to distribute, advertise, or sell the said violative medical device products, otherwise, regulatory actions and sanctions shall be strictly pursued.


All Law Enforcement Agencies (LEAs) and Local Government Units (LGUs) are requested to ensure that these products are not sold or made available in the market or areas of jurisdiction.

The Bureau of Customs is urged to restrain the entry of these misbranded products.

For more information and inquiries about this advisory, kindly contact the FDA CDRRHR through e-mail at cdrrhr@fda.gov.ph indicating on the subject the concerned Advisory, or call (02) 8857-1900 loc. 8301.

To report any sale or distribution of misbranded medical device, contact the online reporting facility **eReport** through e-mail at ereport@fda.gov.ph

Dissemination of this advisory to all concerned is hereby requested.


DR. OSCAR G. GUTIERREZ, JR.
Officer-in-Charge Director General

DTN: 20210923102652 & 20210923102906